转化医学杂志2025，Vol.14Issue(4)：42-46,5.DOI:10.3639/j.issn.2095-3097.2025.04.009
血清Nrf2、HO-1水平与晚期非小细胞肺癌患者靶向治疗效果的关系
The Relationship between Serum Nrf2 and HO-1 Levels and the Therapeutic Effect of Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients
摘要
Abstract
Objective To explore the association between serum levels of nuclear factor erythroid 2-related factor 2(Nrf2)and heme oxygenase 1(HO-1)in patients with advanced non-small cell lung cancer(NSCLC)and their predictive value in predicting the efficacy of targeted therapy.Methods A retrospective analysis was performed on 102 patients with advanced NSCLC who received targeted therapy at Shaanxi Provincial Cancer Hospital from May 2020 to June 2024.Based on treatment response,patients were divided into an effective group(n=56)and an ineffective group(n=46).Serum Nrf2 and HO-1 levels were measured by enzyme-linked immunosorbent assay(ELISA),and differences between pre-and post-treatment levels were analyzed.The predictive value of serum Nrf2 and HO-1 for the therapeutic efficacy was assessed using receiver operating char-acteristic(ROC)curve analysis.Multivariate logistic regression was employed to identify independent factors influencing target-ed therapy outcomes.Results Post-treatment serum Nrf2 and HO-1 levels declined in both groups,but remained significantly higher in the ineffective group compared to the effective group(P＜0.05).ROC analysis showed that the area under the cruve(AUC)values of 0.804(95％CI:0.752-0.854)for Nrf2 and 0.755(95％CI:0.706-0.809)for HO-1 in predicting therapeutic efficacy,with a combined AUC of 0.902(95％CI:0.851-0.954).The effective group exhibited lower proportions of smoking history,stageⅣ pathology,and moderate-to—high tumor differentiation,as well as reduced levels of cancer antigen 123 and carcinoembry-onic antigen(P＜0.05).Multivariate analysis identified stage Ⅳ pathology(OR=2.910,95％CI:1.120-7.557),low differentiation(OR=1.701,95％CI:1.127-2.567),cancer antigen 123(OR=1.002,95％CI:1.008-1.036),Nrf2(OR=5.186,95％CI:1.775-15.152),and HO-1(OR=3.225,95％CI:1.615-6.442)as independent risk factors(P＜0.05).Conclusion Serum Nrf2 and HO-1 levels are significantly associated with targeted therapy efficacy in advanced NSCLC and may serve as predictive bio-markers.Combined assessment of both markers demonstrates superior predictive performance.关键词
核因子E2相关因子2/血红素加氧酶1/晚期非小细胞肺癌/靶向治疗Key words
Nuclear factor erythroid 2-related factor 2/Heme oxygenase 1/Advanced non-small cell lung cancer/Tar-geted therapy分类
医药卫生引用本文复制引用
李丽娜,周菁,王玉珍,焦咪,常琳涵,段炼..血清Nrf2、HO-1水平与晚期非小细胞肺癌患者靶向治疗效果的关系[J].转化医学杂志,2025,14(4):42-46,5.基金项目
陕西省重点研发计划项目(2024SF-YBXM-104) （2024SF-YBXM-104）
陕西省肿瘤医院国家自然科学基金孵育项目(SC23A10) （SC23A10）
